MONMOUTH JUNCTION, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) — Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced debut data from its Phase 3 ALLEVIATE-1 and ALLEVIATE-2 studies evaluating the safety and efficacy of cebranopadol in acute pain will be presented at the American Academy of Pain Medicine (AAPM)…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
TORONTO and PARK CITY, Utah, Aug. 30, 2022 /PRNewswire/ — DW Healthcare Partners (“DWHP”) a healthcare-focused private equity firm, announced the closing of its sale of Med-Pharmex Holdings, Inc (“Med-Pharmex”, or the “Company”) to Dechra […]
Extends the impact of Waystar AltitudeAI, which has prevented $15.5 billion in denials in under one year Leverages a unique combination of proprietary data from more than 7.5 billion annual transactions and one in three […]
CryoEM Confirms a First-in-Class Allosteric Binding Mode, Validating MolecuLern™ AI-Driven Discovery LEHI, Utah, March 14, 2025 /PRNewswire/ — Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of the […]
Copyright © 2026 Biotech Networks
